Estetrol is under clinical development by Gedeon Richter and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Estetrol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Estetrol overview
Esterol (E-4) is under development for the treatment of breast cancer, prostate cancer, vasomotor symptoms of menopause (menopausal hot flashes), genitourinary syndrome of menopause, female sexual arousal disorder (FSAD), vulvovaginal atrophy of menopause, post-menopausal disorders, neonatal hypoxic-ischemic encephalopathy, neuroprotection and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through oral route in the form of tablet and capsule and intravenous route. The drug candidate is a new generation of hormonal replacement therapy. It was also under development for the treatment of osteoporosis, autoimmune disorders and migraine.
Gedeon Richter overview
Gedeon Richter (Richter) is a pharmaceutical company that develops, manufactures and markets a wide range of drugs including original, generic, and licensed products and over the counter (OTC) medicines. The company’s product portfolio consists of medicines to treat gynecological diseases, gastrointestinal diseases, cardiovascular diseases and central nervous system disorders. Richter’s research activities focus exclusively on the development of original small molecules, recombinant biotechnology, and generic product development. It operates sales network in Hungary, Central Eastern Europe, and the Commonwealth of Independent States (CIS) countries. The company has a research and development unit in Central Eastern Europe. Richter is headquartered in Budapest, Hungary.
For a complete picture of Estetrol’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
